Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Basal Cell 25Pancreatic Neoplasms 8Neoplasms 8Prostatic Neoplasms 5Multiple Myeloma 5Medulloblastoma 5Breast Neoplasms 5Skin Neoplasms 4Ovarian Neoplasms 4Basal Cell Nevus Syndrome 4Stomach Neoplasms 3Hematologic Neoplasms 3Colorectal Neoplasms 3Urinary Bladder Neoplasms 2Sarcoma 2Neoplasms, Basal Cell 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Lymphoma 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Glioblastoma 2Chondrosarcoma 2Carcinoma 2Brain Neoplasms 2Adenocarcinoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1

Interventions

Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Filgrastim 2trametinib 1sonidegib 1silmitasertib 1ribociclib 1prexasertib 1pegfilgrastim 1Temozolomide 1HhAntag691 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Microphthalmia, Isolated, with Coloboma 5 × HhAntag691 × Clear all
NCT01601184 2019-05-21

Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway

Centre Leon Berard

Phase 1/2 Terminated
24 enrolled
CNS

Microphthalmia, Isolated, with Coloboma 5, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡